

## Results of Meeting

In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), **PainChek® Ltd (ASX: PCK)** (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, advises the results of its 2024 Annual General Meeting held today.

All resolutions were carried and decided by way of a poll. Details of the resolutions, the proxies, and the votes cast on the poll in respect of each resolution are set out in the attached results.

This announcement has been authorised for release by PainChek CEO Philip Daffas.

### For more information:

Natalie Climo  
Company Secretary, PainChek  
[natalie.climo@boardroomlimited.com.au](mailto:natalie.climo@boardroomlimited.com.au)  
02 8016 2875

Philip Daffas  
CEO, PainChek  
[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)  
0406 537 235

### About PainChek®

[PainChek®](#) is the world’s first regulatory-cleared medical device for the assessment of pain, enabling best-practice pain management for people living with pain in any environment, from those who cannot reliably self-report their pain, those who can, and for those whose ability to self-report their pain fluctuates.

The PainChek® app is available on smartphones and tablets and combines PainChek’s AI pain assessment tool, which intelligently automates the multidimensional pain assessment process, with the Numerical Rating Scale (NRS). This hybrid functionality allows accurate, consistent pain assessment at the point of care, and for care to be considered in PainChek’s detailed reporting suite, PainChek® Analytics.

Globally, PainChek® has attained regulatory clearance as a medical device in Australia, Canada, the European Union, New Zealand, Singapore, Malaysia, and the United Kingdom, with FDA review in the United States currently in progress.

PainChek® has contracts with over 1,600 aged care facilities, with more than 7,000,000 digital pain assessments conducted to date, and is trusted by thousands of nurses, carers, and clinicians.

Using PainChek®, facilities can:

- Ensure greater consistency, continuity, and diagnostic certainty in pain assessment and management by decreasing subjectivity and removing unintentional assessor bias

- Streamline the pain assessment process for time-poor carers, with access to the PainChek® tool, the NRS, pain trends, and charting in one solution
- Simplify record-keeping and documentation to demonstrate compliance and support funding claims, with all historical pain assessment data in one place
- Enhance engagement with GPs and allied healthcare professionals

Clinical studies conducted in Australian and UK residential aged care centres have been published in various peer-reviewed journals including the [Journal of Alzheimer's Disease](#). An article in [BMC Geriatrics](#) indicates that PainChek® is a valid and reliable instrument to assess the presence and severity of pain in people with moderate-to-severe dementia living in aged care. Further information on clinical studies can be found [here](#).

PainChek® has successfully supported accurate pain assessment and management for thousands of adults worldwide living with dementia, disability, or other conditions impacting their ability to self-report pain. Building on the success of this technology, the clinically validated [PainChek® Infant app](#) identifies and detects six facial action units indicative of pain in infants aged one month to 12 months.

The need for PainChek as a best-practice pain management solution also extends to older people living at home and with access to home care packages that enable long-term home living. PainChek is expanding into home care by partnering with home care and disability service providers.

For more information, visit: <https://painchek.com>

**PainChek Ltd**  
**Annual General Meeting**  
**Thursday, 28 November 2024**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1. Adoption of Remuneration Report	Ordinary	166,257,273 94.99%	3,553,036 2.03%	5,210,640 2.98%	279,587	171,992,913 97.98%	3,553,036 2.02%	289,390	Carried	No
2. Re-Election of Director - Mr Adam Davey	Ordinary	167,453,219 86.25%	3,304,731 1.70%	23,386,369 12.05%	387,587	226,876,066 98.56%	3,304,731 1.44%	397,390	Carried	N/A
3. Re-Election of Director - Ms Cynthia Payne	Ordinary	167,489,469 86.21%	3,257,981 1.68%	23,534,456 12.11%	250,000	227,060,403 98.59%	3,257,981 1.41%	259,803	Carried	N/A
4. Approval of 10% Placement Capacity (Special Resolution)	Special	166,716,795 85.77%	4,141,155 2.13%	23,523,956 12.10%	150,000	226,277,229 98.20%	4,141,155 1.80%	159,803	Carried	N/A
5. Ratification of Prior Issue of the Balance Tranche 2 Placement Shares (November 2023)	Ordinary	168,011,618 94.35%	2,736,332 1.54%	7,313,074 4.11%	260,000	184,170,812 98.54%	2,736,332 1.46%	269,803	Carried	N/A
6. Ratification of Prior Issue of Placement Shares (March 2024)	Ordinary	167,550,761 86.24%	3,197,189 1.65%	23,523,956 12.11%	260,000	227,111,195 98.61%	3,197,189 1.39%	269,803	Carried	N/A

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.